Skip to content
OpenCapital
Get started

TransMedics Group, Inc. TMDX Heart Product — Revenue

Other product segments

Liver Product
$138.98M+27.7%
Lung Product
$2.82M-29.6%

Similar metrics at other companies

Organon logo
OGNOther Cardiovascular — Revenue
$28M-6.7%
STERIS logo
STEProduct — Revenue
$845.3M+5.5%
Bausch Health Companies logo
BHCProduct sales — Revenue
$2.5B+12.3%
Lantheus Holdings logo
LNTHCardiology — Revenue
$84.63M+6.8%
Johnson & Johnson logo
JNJother cardiovascular — Sales to Customers
$99.25M+4.5%
10x Genomics, Inc. logo
TXGProducts and services revenue — Revenue
$149.9M+8.8%

Other financials

Income statement

See full
Revenue$173.9M+21.2%
Gross profit$101.2M+14.7%
Operating income$13.3M-51.5%
Net income$7.3M-71.5%
EPS (diluted)$0.20-71.4%

Balance sheet

See full
Cash & equivalents$461.7M+48.9%
Total debt$409.9M+505%
Total equity$494.0M+85.5%
Total assets$1.4B+71.3%

Cash flow

See full
Operating cash flow$24.5M+959%
CapEx$36.7M+35.6%
Free cash flow-$12.1M+59.4%

Valuation

See full
Market cap$2.55B+50.6%
Enterprise value$2.5B+66.0%
P/E14.8×-19.8×
P/S4×+0.5×

Profitability

See full
Gross margin59.1%-0.4pp
Operating margin14.9%+4.1pp
Net margin27%+17.0pp
FCF margin23.8%—

Returns & leverage

See full
Return on equity45.2%+22.2pp
Debt / equity0.8×+0.6×
Current ratio6.7×-2.4×

Where this comes from

Reported directly by TransMedics Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about TransMedics Group, Inc.'s heart product — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TransMedics Group, Inc.'s heart product — revenue?
TransMedics Group, Inc. (TMDX) reported heart product — revenue of $30.87M in Q1 2026.
How has TransMedics Group, Inc.'s heart product — revenue changed year-over-year?
TransMedics Group, Inc.'s heart product — revenue increased by 3.5% year-over-year, from $29.82M to $30.87M.
What is the long-term trend for TransMedics Group, Inc.'s heart product — revenue?
Over 4 years (2021 to 2025), TransMedics Group, Inc.'s heart product — revenue has grown at a 63.4% compound annual growth rate (CAGR), from $17.68M to $126.01M.
What does heart product — revenue mean?
This metric represents the total gross sales generated from the sale and service of heart-related organ perfusion and monitoring technologies. It reflects the market adoption and commercial performance of the company's specialized medical devices designed to preserve donor hearts outside the body. Growth in this revenue stream indicates successful penetration into the organ transplant clinical market and the expansion of the installed base for heart-specific medical solutions.